Abstract: Alzheimer’s disease (AD) (a progressive neurodegenerative disorder) is mostly predominant cause of dementia in the elderly. Prolonging the function of acetylcholine by inhibiting both acetylcholinesterase and butyrylcholinesterase is most effective treatment therapy of AD. Traditionally Pterocarpus santalinus L. is widely known for its medicinal use. In this study, in vitro acetylcholinesterase inhibitory activity was investigated and methanolic extract of the plant showed significant activity. To confirm this activity (in vivo), learning and memory enhancing effects were tested in mice. For the test, memory impairment was induced by scopolamine (cholinergic muscarinic receptor antagonist). Anti-amnesic effect of the extract was investigated by the passive avoidance task in mice. The study also includes brain acetylcholinesterase activity. Results proved that scopolamine induced cognitive dysfunction was significantly decreased by administration of the extract solution, in the passive avoidance task and inhibited brain acetylcholinesterase activity. These results suggest that bark extract of Pterocarpus santalinus can be better option for further studies on AD via their acetylcholinesterase inhibitory actions.
Abstract: The goal of this paper is to present the diagnostic
contribution that the screening instrument, Mini-Mental State
Examination-2: Expanded Version (MMSE-2:EV), brings in
detecting the cognitive impairment or in monitoring the progress of
degenerative disorders. The diagnostic signification is underlined by
the interpretation of the MMSE-2:EV scores, resulted from the test
application to patients with mild and major neurocognitive disorders.
The cases were selected from current practice, in order to cover vast
and significant neurocognitive pathology: mild cognitive impairment,
Alzheimer’s disease, vascular dementia, mixed dementia, Parkinson’s
disease, conversion of the mild cognitive impairment into
Alzheimer’s disease. The MMSE-2:EV version was used: it was
applied one month after the initial assessment, three months after the
first reevaluation and then every six months, alternating the blue and
red forms. Correlated with age and educational level, the raw scores
were converted in T scores and then, with the mean and the standard
deviation, the z scores were calculated. The differences of raw scores
between the evaluations were analyzed from the point of view of
statistic signification, in order to establish the progression in time of
the disease. The results indicated that the psycho-diagnostic approach
for the evaluation of the cognitive impairment with MMSE-2:EV is
safe and the application interval is optimal. In clinical settings with a
large flux of patients, the application of the MMSE-2:EV is a safe
and fast psychodiagnostic solution. The clinicians can draw objective
decisions and for the patients: it does not take too much time and
energy, it does not bother them and it doesn’t force them to travel
frequently.